Fulcrum Therapeutics Inc (FULC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Fulcrum Therapeutics Inc (FULC) has a cash flow conversion efficiency ratio of -0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.19 Million) by net assets ($198.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Fulcrum Therapeutics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Fulcrum Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Fulcrum Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Fulcrum Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fulcrum Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FG Imperii Acquisition Corp. Class A Ordinary Shares
NASDAQ:FGII
|
0.006x |
|
Shenzhen Wongtee International Enterprise Co Ltd
SHE:000056
|
-0.028x |
|
Wintec Co. Ltd
KQ:320000
|
-0.043x |
|
Toyota Caetano
LS:SCT
|
-0.017x |
|
Starz Entertainment LLC
NASDAQ:STRZ
|
-0.033x |
|
Indoco Remedies Limited
NSE:INDOCO
|
0.169x |
|
Can2 Termik AS
IS:CANTE
|
0.020x |
|
STINAG Stuttgart Invest AG
F:STG
|
N/A |
Annual Cash Flow Conversion Efficiency for Fulcrum Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Fulcrum Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Fulcrum Therapeutics Inc (FULC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $243.03 Million | $-2.22 Million | -0.009x | +97.64% |
| 2023-12-31 | $235.19 Million | $-90.97 Million | -0.387x | +20.72% |
| 2022-12-31 | $198.94 Million | $-97.05 Million | -0.488x | -31.50% |
| 2021-12-31 | $211.54 Million | $-78.48 Million | -0.371x | +34.19% |
| 2020-12-31 | $95.18 Million | $-53.66 Million | -0.564x | -24.43% |
| 2019-12-31 | $87.15 Million | $-39.48 Million | -0.453x | -52.60% |
| 2018-12-31 | $76.00 Million | $-22.56 Million | -0.297x | +98.04% |
| 2017-12-31 | $1.32 Million | $-20.07 Million | -15.185x | -- |
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalasse… Read more